Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) insider Jennifer Michaelson sold 4,000 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $12.36, for a total value of $49,440.00. Following the sale, the insider owned 158,649 shares in the company, valued at $1,960,901.64. This trade represents a 2.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Jennifer Michaelson also recently made the following trade(s):
- On Tuesday, September 8th, Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $21.57, for a total value of $172,560.00.
- On Thursday, August 13th, Jennifer Michaelson sold 30,000 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $20.26, for a total value of $607,800.00.
Cullinan Therapeutics Stock Performance
NASDAQ CGEM traded up $0.51 during trading hours on Friday, hitting $11.31. 755,506 shares of the company’s stock were exchanged, compared to its average volume of 735,942. The business’s 50 day moving average is $16.97 and its 200-day moving average is $15.83. Cullinan Therapeutics, Inc. has a 12-month low of $6.73 and a 12-month high of $23.19. The firm has a market capitalization of $727.91 million, a P/E ratio of -3.65 and a beta of -0.03.
Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.01). As a group, equities research analysts anticipate that Cullinan Therapeutics, Inc. will post -3.06 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on CGEM. BTIG Research boosted their target price on Cullinan Therapeutics from $40.00 to $41.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Friday, October 2nd. Wall Street Zen cut shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 24th. Wedbush boosted their price objective on shares of Cullinan Therapeutics from $39.00 to $42.00 and gave the stock an “outperform” rating in a research note on Thursday, August 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Cullinan Therapeutics in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.86.
Read Our Latest Stock Analysis on CGEM
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Cullinan Therapeutics during the 2nd quarter valued at $95,289,000. Blue Owl Capital Holdings LP purchased a new stake in shares of Cullinan Therapeutics during the second quarter worth about $28,039,000. Dimensional Fund Advisors LP increased its position in shares of Cullinan Therapeutics by 6.7% during the first quarter. Dimensional Fund Advisors LP now owns 906,028 shares of the company’s stock worth $12,870,000 after acquiring an additional 57,259 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of Cullinan Therapeutics by 2,125.0% in the third quarter. Fisher Asset Management LLC now owns 800,961 shares of the company’s stock worth $12,295,000 after acquiring an additional 764,963 shares in the last quarter. Finally, Boone Capital Management LLC purchased a new position in Cullinan Therapeutics in the second quarter valued at about $12,828,000. 86.31% of the stock is owned by institutional investors and hedge funds.
Cullinan Therapeutics Company Profile
Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer. The company builds a portfolio of targeted therapies and immune-modulating treatments designed to address significant unmet needs across hematologic malignancies and solid tumors.
Its development programs include investigational antibody-based therapies and other biologic approaches intended to selectively target cancer cells or activate the immune system. Among its programs are CLN-619, an antibody directed at the MICA and MICB proteins, CLN-418, an immune-activating bispecific molecule, and CLN-049, an investigational treatment designed to engage FLT3 and FLT3 ligand in certain blood cancers.
Read More
- Five stocks we like better than Cullinan Therapeutics
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
Receive News & Ratings for Cullinan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
